Skip to main content
PMC home page
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 1985 Feb;78(2):129–135. doi: 10.1177/014107688507800212

Hormonal aspects of prostatic cancer: a review.

J Waxman
PMCID: PMC1289584  PMID: 2983074

Full text

PDF
134

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed S. R., Brooman P. J., Shalet S. M., Howell A., Blacklock N. J., Rickards D. Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms. Lancet. 1983 Aug 20;2(8347):415–419. doi: 10.1016/s0140-6736(83)90387-2. [DOI] [PubMed] [Google Scholar]
  2. Allen J. M., Kerle D. J., Ware H., Doble A., Williams G., Bloom S. R. Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer. Br Med J (Clin Res Ed) 1983 Dec 10;287(6407):1766–1766. doi: 10.1136/bmj.287.6407.1766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Allen J. M., O'Shea J. P., Mashiter K., Williams G., Bloom S. R. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist. Br Med J (Clin Res Ed) 1983 May 21;286(6378):1607–1609. doi: 10.1136/bmj.286.6378.1607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. BUELL P., DUNN J. E., Jr CANCER MORTALITY AMONG JAPANESE ISSEI AND NISEI OF CALIFORNIA. Cancer. 1965 May;18:656–664. doi: 10.1002/1097-0142(196505)18:5<656::aid-cncr2820180515>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  5. Baker H. W., Burger H. G., De Kretser D. M., Hudson B., Straffon W. G. Effects of synthetic oral oestrogens in normal men and patients with prostatic carcinoma: lack of gonadotrophin suppression by chlorotrianisene. Clin Endocrinol (Oxf) 1973 Oct;2(4):297–306. doi: 10.1111/j.1365-2265.1973.tb01715.x. [DOI] [PubMed] [Google Scholar]
  6. Belchetz P. E., Plant T. M., Nakai Y., Keogh E. J., Knobil E. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science. 1978 Nov 10;202(4368):631–633. doi: 10.1126/science.100883. [DOI] [PubMed] [Google Scholar]
  7. Bergquist C., Nillius S. J., Bergh T., Skarin G., Wide L. Inhibitory effects on gonadotrophin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue. Acta Endocrinol (Copenh) 1979 Aug;91(4):601–608. doi: 10.1530/acta.0.0910601. [DOI] [PubMed] [Google Scholar]
  8. Bergquist C., Nillius S. J., Wide L. Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist. Contraception. 1979 May;19(5):497–506. doi: 10.1016/0010-7824(79)90064-7. [DOI] [PubMed] [Google Scholar]
  9. Bhanalaph T., Varkarakis M. J., Murphy G. P. Current status of bilateral adrenalectomy or advanced prostatic carcinoma. Ann Surg. 1974 Jan;179(1):17–23. doi: 10.1097/00000658-197401000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Biorn C. L., Gray C. P., Strauss E. Urology-epitomes of progress: orchiectomy after presumed estrogen failure in treatment of carcinoma of the prostate. West J Med. 1979 Apr;130(4):363–364. [PMC free article] [PubMed] [Google Scholar]
  11. Blackard C. E., Byar D. P., Jordan W. P., Jr Orchiectomy for advanced prostatic carcinoma. A reevaluation. Urology. 1973 Jun;1(6):553–560. doi: 10.1016/0090-4295(73)90515-3. [DOI] [PubMed] [Google Scholar]
  12. Bourne G. A., Regiani S., Payne A. H., Marshall J. C. Testicular GnRH receptors--characterization and localization on interstitial tissue. J Clin Endocrinol Metab. 1980 Aug;51(2):407–409. doi: 10.1210/jcem-51-2-407. [DOI] [PubMed] [Google Scholar]
  13. Boyns A. R., Cole E. N., Phillips M. E., Hillier S. G., Cameron E. H., Griffiths K., Shahmanesh M., Feneley R. C., Hartog M. Plasma prolactin, GH, LH, FSH, TSH and testosterone during treatment of prostatic carcinoma with oestrogens. Eur J Cancer. 1974 Jul;10(7):445–449. doi: 10.1016/0014-2964(74)90028-0. [DOI] [PubMed] [Google Scholar]
  14. Brendler H. Adrenalectomy and hypophysectomy for prostatic cancer. Urology. 1973 Aug;2(2):99–102. doi: 10.1016/0090-4295(73)90238-0. [DOI] [PubMed] [Google Scholar]
  15. Byar D. P. Treatment of prostatic cancer: studies by the Veterans Administration cooperative urological research group. Bull N Y Acad Med. 1972 Jun;48(5):751–766. [PMC free article] [PubMed] [Google Scholar]
  16. Catalona W. J., Scott W. W. Carcinoma of the prostate: a review. J Urol. 1978 Jan;119(1):1–8. doi: 10.1016/s0022-5347(17)57365-6. [DOI] [PubMed] [Google Scholar]
  17. Chaisiri N., Valotaire Y., Evans B. A., Pierrepoint C. G. Demonstration of a cytoplasmic receptor protein for oestrogen in the canine prostate gland. J Endocrinol. 1978 Jul;78(1):131–139. doi: 10.1677/joe.0.0780131. [DOI] [PubMed] [Google Scholar]
  18. Clark P., Houghton L. Subcapsular orchidectomy for carcinoma of the prostate. Br J Urol. 1977 Oct;49(5):419–425. doi: 10.1111/j.1464-410x.1977.tb04169.x. [DOI] [PubMed] [Google Scholar]
  19. Coy D. H., Schally A. V. Gonadotrophin releasing hormone analogues. Ann Clin Res. 1978;10(3):139–144. [PubMed] [Google Scholar]
  20. DeFelice R., Johnson D. G., Galgiani J. N. Gynecomastia with ketoconazole. Antimicrob Agents Chemother. 1981 Jun;19(6):1073–1074. doi: 10.1128/aac.19.6.1073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ekman P., Snochowski M., Zetterberg A., Högberg B., Gustafsson J. A. Steroid receptor content in human prostatic carcinoma and response to endocrine therapy. Cancer. 1979 Oct;44(4):1173–1181. doi: 10.1002/1097-0142(197910)44:4<1173::aid-cncr2820440402>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  22. Franchimont P. Pituitary gonadotrophins. Clin Endocrinol Metab. 1977 Mar;6(1):101–116. doi: 10.1016/s0300-595x(77)80058-3. [DOI] [PubMed] [Google Scholar]
  23. Geller J., Cantor T., Albert J. Evidence for a specific dihydrotestosterone-binding cytosol receptor in the human prostate. J Clin Endocrinol Metab. 1975 Nov;41(5):854–862. doi: 10.1210/jcem-41-5-854. [DOI] [PubMed] [Google Scholar]
  24. Girard J., Baumann J. B. Proceedings: Secondary adrenal insufficiency due to cyproterone acetate. J Endocrinol. 1976 Jun;69(3):13P–14P. [PubMed] [Google Scholar]
  25. Glick J. H., Wein A., Padavic K., Negendank W., Harris D., Brodovsky H. Phase II trial of tamoxifen in metastatic carcinoma of the prostate. Cancer. 1982 Apr 1;49(7):1367–1372. doi: 10.1002/1097-0142(19820401)49:7<1367::aid-cncr2820490711>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  26. Glick J. H., Wein A., Padavic K., Negendank W., Harris D., Brodovsky H. Tamoxifen in refractory metastatic carcinoma of the prostate. Cancer Treat Rep. 1980 Jun-Jul;64(6-7):813–818. [PubMed] [Google Scholar]
  27. Hsueh A. J., Erickson G. F. Extrapituitary action of gonadotropin-releasing hormone: direct inhibition ovarian steroidogenesis. Science. 1979 May 25;204(4395):854–855. doi: 10.1126/science.375393. [DOI] [PubMed] [Google Scholar]
  28. Huggins C., Scott W. W. Bilateral Adrenalectomy in Prostatic Cancer: Clinical Features and Urinary Excretion of 17-Ketosteroids and Estrogen. Ann Surg. 1945 Dec;122(6):1031–1041. [PMC free article] [PubMed] [Google Scholar]
  29. Lepor H., Ross A., Walsh P. C. The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol. 1982 Aug;128(2):335–340. doi: 10.1016/s0022-5347(17)52915-8. [DOI] [PubMed] [Google Scholar]
  30. Monahan M. W., Amoss M. S., Anderson H. A., Vale W. Synthetic analogs of the hypothalamic luteinizing hormone releasing factor with increased agonist or antagonist properties. Biochemistry. 1973 Nov 6;12(23):4616–4620. doi: 10.1021/bi00747a012. [DOI] [PubMed] [Google Scholar]
  31. NESBIT R. M., BAUM W. C. Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases. J Am Med Assoc. 1950 Aug 12;143(15):1317–1320. doi: 10.1001/jama.1950.02910500019005. [DOI] [PubMed] [Google Scholar]
  32. Pont A., Williams P. L., Loose D. S., Feldman D., Reitz R. E., Bochra C., Stevens D. A. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med. 1982 Sep;97(3):370–372. doi: 10.7326/0003-4819-97-3-370. [DOI] [PubMed] [Google Scholar]
  33. Prout G. R., Jr, Brewer W. R. Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer. 1967 Nov;20(11):1871–1878. doi: 10.1002/1097-0142(196711)20:11<1871::aid-cncr2820201112>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  34. Redding T. W., Coy D. H., Schally A. V. Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1982 Feb;79(4):1273–1276. doi: 10.1073/pnas.79.4.1273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Resnick M. I., Grayhack J. T. Treatment of stage IV carcinoma of the prostate. Urol Clin North Am. 1975 Feb;2(1):141–161. [PubMed] [Google Scholar]
  36. Reynoso G., Murphy G. P. Adrenalectomy and hypophysectomy in advanced prostatic carcinoma. Cancer. 1972 Apr;29(4):941–945. doi: 10.1002/1097-0142(197204)29:4<941::aid-cncr2820290440>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  37. Sanford E. J., Drago J. R., Rohner T. J., Jr, Santen R., Lipton A. Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma. J Urol. 1976 Feb;115(2):170–174. doi: 10.1016/s0022-5347(17)59121-1. [DOI] [PubMed] [Google Scholar]
  38. Schally A. V., Nair R. M., Carter W. H. Countercurrent distribution as a tool for purification of hypothalamic hormones on a preparative scale. Anal Chem. 1971 Sep;43(11):1527–1529. doi: 10.1021/ac60305a035. [DOI] [PubMed] [Google Scholar]
  39. Shearer R. J., Hendry W. F., Sommerville I. F., Fergusson J. D. Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer. Br J Urol. 1973 Dec;45(6):668–677. doi: 10.1111/j.1464-410x.1973.tb12238.x. [DOI] [PubMed] [Google Scholar]
  40. Siiteri P. K., Wilson J. D. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest. 1970 Sep;49(9):1737–1745. doi: 10.1172/JCI106391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Silverberg G. D. Hypophysectomy in the treatment of disseminated prostate carcinoma. Cancer. 1977 Apr;39(4):1727–1731. doi: 10.1002/1097-0142(197704)39:4<1727::aid-cncr2820390451>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  42. Sinha A. A., Blackard C. E., Doe R. P., Seal U. S. The in vitro localization of H 3 estradiol in human prostatic carcinoma. An electron microscopic autoradiographic study. Cancer. 1973 Mar;31(3):682–688. doi: 10.1002/1097-0142(197303)31:3<682::aid-cncr2820310330>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  43. Spremulli E., DeSimone P., Durant J. A phase II study Nolvadex: tamoxifen citrate in the treatment of advanced prostatic adenocarcinoma. Am J Clin Oncol. 1982 Apr;5(2):149–153. doi: 10.1097/00000421-198204000-00061. [DOI] [PubMed] [Google Scholar]
  44. Stone A. R., Hargreave T. B., Chisholm G. D. The diagnosis of oestrogen escape and the role of secondary orchiectomy in prostatic cancer. Br J Urol. 1980 Dec;52(6):535–538. doi: 10.1111/j.1464-410x.1980.tb03109.x. [DOI] [PubMed] [Google Scholar]
  45. Tharandt L., Schulte H., Benker G., Hackenberg K., Reinwein D. Treatment of isolated gonadotropin deficiency in men with synthetic LR-RH and a more potent analogue of LH-RH. Neuroendocrinology. 1977;24(3-4):195–207. doi: 10.1159/000122708. [DOI] [PubMed] [Google Scholar]
  46. Tolis G., Ackman D., Stellos A., Mehta A., Labrie F., Fazekas A. T., Comaru-Schally A. M., Schally A. V. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A. 1982 Mar;79(5):1658–1662. doi: 10.1073/pnas.79.5.1658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Trachtenberg J., Halpern N., Pont A. Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J Urol. 1983 Jul;130(1):152–153. doi: 10.1016/s0022-5347(17)51007-1. [DOI] [PubMed] [Google Scholar]
  48. Walker K. J., Nicholson R. I., Turkes A. O., Turkes A., Griffiths K., Robinson M., Crispin Z., Dris S. Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma. Lancet. 1983 Aug 20;2(8347):413–415. doi: 10.1016/s0140-6736(83)90386-0. [DOI] [PubMed] [Google Scholar]
  49. Waxman J. H., Wass J. A., Hendry W. F., Whitfield H. N., Besser G. M., Malpas J. S., Oliver R. T. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br Med J (Clin Res Ed) 1983 Apr 23;286(6374):1309–1312. doi: 10.1136/bmj.286.6374.1309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Worgul T. J., Santen R. J., Samojlik E., Veldhuis J. D., Lipton A., Harvey H. A., Drago J. R., Rohner T. J. Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma. J Urol. 1983 Jan;129(1):51–55. doi: 10.1016/s0022-5347(17)51916-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES